MBX Biosciences, Inc. MBX R2K
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -77.6% CAGR over 5 years.
- Trading 27.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MBX MBX Biosciences, Inc. R2K | 31.47 | - | $1.50B | - | -26.53% | -25.73% | - | -77.59% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 26.53M | 21.80M | 23.93M | 25.80M | 27.27M |
| Operating Income | - | - | -10.95M | -13.31M | -16.66M | -19.61M | -26.53M | -21.80M | -23.93M | -25.80M | -27.27M |
| EBITDA | - | - | - | - | - | - | -26.45M | -21.74M | -23.88M | -25.73M | -27.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.95M | -7.61M | -10.16M | -12.34M | -15.86M | -18.14M | -23.88M | -19.41M | -21.62M | -22.06M | -23.52M |
| Diluted EPS | - | - | -9.40 | -10.26 | -12.62 | -2.78 | -0.71 | -0.58 | -0.63 | -0.49 | -0.50 |
| R&D Expense | - | - | 9.07M | 11.05M | 14.40M | 16.75M | 22.41M | 17.72M | 19.27M | - | 18.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Operating Income | -25.16M | -35.31M | -68.19M | -98.06M |
| EBITDA | -25.70M | -35.15M | -67.95M | -97.81M |
| Interest Expense | 374.00K | 0 | - | - |
| Pretax Income | -26.14M | -32.56M | -61.92M | -86.97M |
| Tax Provision | - | - | - | - |
| Net Income | -26.14M | -32.56M | -61.92M | -86.97M |
| Diluted EPS | -0.82 | -1.02 | -5.82 | - |
| R&D Expense | - | 28.53M | 57.41M | 79.16M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -77.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +153.38% |
| 6 Months: | -0.41% |
| 3 Months: | -3.32% |
| 1 Month: | +10.00% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 45.09M | 84.18M | 268.54M | 385.14M |
| Current Assets | 44.21M | 83.47M | 267.29M | 381.54M |
| Cash & Equivalents | 24.21M | 30.52M | 49.35M | 75.29M |
| Inventory | - | - | - | - |
| Receivables | 142.00K | 208.00K | 682.00K | 2.12M |
| Total Liabilities | 87.70M | 156.65M | 11.09M | 15.92M |
| Current Liabilities | 3.43M | 3.93M | 11.05M | 15.49M |
| Long Term Debt | - | - | - | - |
| Total Debt | 461.00K | 324.00K | 171.00K | 596.00K |
| Total Equity | -42.60M | -72.47M | 257.44M | 369.22M |
| Shares Outstanding | 31.85M | 31.85M | 33.42M | 44.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -23.12M | -31.98M | -54.68M | -79.95M |
| Investing Cash Flow | -11.41M | -30.93M | -160.59M | -83.70M |
| Financing Cash Flow | 46.06M | 69.22M | 234.10M | 189.59M |
| Capital Expenditure | -441.00K | -129.00K | -874.00K | -1.93M |
| Free Cash Flow | -23.56M | -32.11M | -55.55M | -81.88M |
| Net Change in Cash | 11.53M | 6.31M | 18.83M | 25.94M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 61.3% | 44.9% | -24.1% | -23.6% |
| ROCE % | -60.4% | -44.0% | -26.5% | -26.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 13.98% | 6.65M | $209.34M |
| 2 | Orbimed Advisors LLC. | 7.64% | 3.64M | $114.48M |
| 3 | NEA Management Company, LLC | 7.59% | 3.61M | $113.75M |
| 4 | Wellington Management Group, LLP | 6.71% | 3.19M | $100.45M |
| 5 | Blackrock Inc. | 6.18% | 2.94M | $92.57M |
| 6 | FMR, LLC | 6.17% | 2.94M | $92.42M |
| 7 | Deep Track Capital, Lp | 5.79% | 2.76M | $86.78M |
| 8 | NVP Associates, LLC | 4.49% | 2.14M | $67.23M |
| 9 | Polar Capital Holdings PLC | 3.41% | 1.62M | $51.05M |
| 10 | Braidwell LP | 3.14% | 1.49M | $46.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBX